pdufa.bio
CalendarDecisionsApprovals/yrTrial oddsLearnResearchMethodology
Home › PDUFA Calendar › GILD

GILD PDUFA Date: Bictegravir and Lenacapavir

FDA decision (PDUFA) target 2026-08-27 · Gilead Sciences Inc. · HIV

GILD run-up into the PDUFA (last ~120 days)

$152.74$121.48
Price path to 2026-06-19. Green = local high, red = low/sell-off. Historical price action, not a forecast.

Key facts

FDA PDUFA target date2026-08-27
Drug / candidateBictegravir and Lenacapavir
IndicationHIV
CompanyGilead Sciences Inc.
Market-cap tierLarge
Cohort decision-day move (history)±1% median
ClinicalTrials.govNCT06333808 · active

New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs.

Track this live → price, options (expected move & IV) and the full dashboard
Opens the pdufa.bio app (private beta)

FAQ

When is the GILD PDUFA date?
The FDA PDUFA target date for GILD (Gilead Sciences Inc.) is 2026-08-27 for Bictegravir and Lenacapavir. Dates are company/FDA-sourced and can slip — verify against primary filings.
What is GILD's drug Bictegravir and Lenacapavir?
Bictegravir and Lenacapavir is Gilead Sciences Inc.'s candidate under FDA review for HIV.
What typically happens to a large-cap stock into a PDUFA date?
Historically, large-cap names had a median decision-day move around ±1% (694-PDUFA cohort, 2024–26). This is historical context by market-cap tier, not a prediction for this drug.